“The benefit of their formulation … is it’s remarkably scalable, so they can scale to a very high number of doses,” said Matthew Frieman, a coronavirus expert at the U-Md. School of Medicine who began collaborating with the company in 2012, on a vaccine for a different coronavirus, Middle East respiratory syndrome. “It’s not a super-strange production platform … you don’t need super-specialized facilities. It’s stable, so you don’t need severe cold chain” to store the vaccine.
View original article here Source